Replies to post #221030 on Biotech Values

[DewDiligence]

SNDX -20% on no news—sell-off could be related to recent general bearishness for PD-(L1) add-on agents, which was a theme at ESMO.

[DewDiligence]

SNDX -21%/AH on PFS failure in HR+/HER2- breast cancer:

https://finance.yahoo.com/news/syndax-host-conference-call-phase-200500374.html

The trial continues to test for statsig OS every six months until Nov 2019.